BTX 2640
Alternative Names: BTX-2640Latest Information Update: 03 Oct 2023
At a glance
- Originator BioTheryX
- Class Anti-inflammatories; Antineoplastics; Small molecules
- Mechanism of Action Proteolysis; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Cancer; Inflammation
Most Recent Events
- 03 Oct 2023 Suspended for Cancer in USA (unspecified route) (Biotheryx pipeline, August 2023)
- 30 Aug 2023 Suspended for Inflammation in USA (unspecified route) before August 2023 (Biotheryx pipeline, August 2023)
- 10 May 2023 BTX 2640 is available for licensing as of 09 May 2023. https://www.biotheryx.com/pipeline/